ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Chicago, IL, USA:

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-s...

Enrolling
Ovarian Cancer
Drug: Durvalumab
Drug: BA3011

Phase 2

Canadian Cancer Trials Group

Chicago, Illinois, United States and 6 other locations

and further the remissions and duration of remissions with standard ovarian cancer chemotherapy with carboplatin and paclitaxel. As...

Enrolling
Ovarian Cancer
Drug: Selinexor
Drug: Paclitaxel

Phase 2

Loyola University

Maywood, Illinois, United States

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Durvalumab placebo
Drug: Bevacizumab

Phase 3

AstraZeneca
AstraZeneca

Hinsdale, Illinois, United States and 213 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Evanston, Illinois, United States and 125 other locations

mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in...

Active, not recruiting
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Pegylated Liposomal Doxorubicin + SL-172154
Drug: Mirvetuximab + SL-172154

Phase 1

Shattuck Labs

Chicago, Illinois, United States and 20 other locations

efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian...

Enrolling
Fallopian Tube Cancer
Ovarian Cancer
Drug: ONC-392
Drug: Pembrolizumab

Phase 2

OncoC4

Hinsdale, Illinois, United States and 20 other locations

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Chicago, Illinois, United States and 46 other locations

positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...

Active, not recruiting
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin

Phase 2

ImmunoGen
ImmunoGen

Chicago, Illinois, United States and 70 other locations

This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-...

Enrolling
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Biological: AB-1015

Phase 1

ArsenalBio

Chicago, Illinois, United States and 9 other locations

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Evanston, Illinois, United States and 31 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems